310 related articles for article (PubMed ID: 28254508)
1. Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D
Fazio P; Schain M; Mrzljak L; Amini N; Nag S; Al-Tawil N; Fitzer-Attas CJ; Bronzova J; Landwehrmeyer B; Sampaio C; Halldin C; Varrone A
Neuroimage; 2017 May; 152():330-339. PubMed ID: 28254508
[TBL] [Abstract][Full Text] [Related]
2. In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [
Svedberg MM; Varnäs K; Varrone A; Mitsios N; Mulder J; Gulyás B; Beaumont V; Munoz-Sanjuan I; Zaleska MM; Schmidt CJ; Halldin C; Mrzljak L
Brain Res; 2019 May; 1711():140-145. PubMed ID: 30664847
[TBL] [Abstract][Full Text] [Related]
3. In vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654.
Barret O; Thomae D; Tavares A; Alagille D; Papin C; Waterhouse R; McCarthy T; Jennings D; Marek K; Russell D; Seibyl J; Tamagnan G
J Nucl Med; 2014 Aug; 55(8):1297-304. PubMed ID: 24898025
[TBL] [Abstract][Full Text] [Related]
4. Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study.
Abi-Jaoude E; Segura B; Obeso I; Cho SS; Houle S; Lang AE; Rusjan P; Sandor P; Strafella AP
Hum Brain Mapp; 2015 Jul; 36(7):2592-601. PubMed ID: 25788222
[TBL] [Abstract][Full Text] [Related]
5. The relationship between subcortical brain volume and striatal dopamine D
Caravaggio F; Ku Chung J; Plitman E; Boileau I; Gerretsen P; Kim J; Iwata Y; Patel R; Chakravarty MM; Remington G; Graff-Guerrero A
Hum Brain Mapp; 2017 Nov; 38(11):5519-5534. PubMed ID: 28752565
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex.
Häggkvist J; Tóth M; Tari L; Varnäs K; Svedberg M; Forsberg A; Nag S; Dominguez C; Munoz-Sanjuan I; Bard J; Wityak J; Varrone A; Halldin C; Mrzljak L
J Nucl Med; 2017 Apr; 58(4):617-622. PubMed ID: 27856625
[TBL] [Abstract][Full Text] [Related]
7. Rostrocaudal gradients of dopamine D2/3 receptor binding in striatal subregions measured with [(11)C]raclopride and high-resolution positron emission tomography.
Alakurtti K; Johansson JJ; Tuokkola T; Någren K; Rinne JO
Neuroimage; 2013 Nov; 82():252-9. PubMed ID: 23727314
[TBL] [Abstract][Full Text] [Related]
8. Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers.
Matuskey D; Worhunksy P; Correa E; Pittman B; Gallezot JD; Nabulsi N; Ropchan J; Sreeram V; Gudepu R; Gaiser E; Cosgrove K; Ding YS; Potenza MN; Huang Y; Malison RT; Carson RE
Neuroimage; 2016 Apr; 130():241-247. PubMed ID: 26876475
[TBL] [Abstract][Full Text] [Related]
9. In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects.
Delnomdedieu M; Forsberg A; Ogden A; Fazio P; Yu CR; Stenkrona P; Duvvuri S; David W; Al-Tawil N; Vitolo OV; Amini N; Nag S; Halldin C; Varrone A
Neuropharmacology; 2017 May; 117():171-181. PubMed ID: 28122201
[TBL] [Abstract][Full Text] [Related]
10. Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging.
Russell DS; Jennings DL; Barret O; Tamagnan GD; Carroll VM; Caillé F; Alagille D; Morley TJ; Papin C; Seibyl JP; Marek KL
Neurology; 2016 Feb; 86(8):748-54. PubMed ID: 26802091
[TBL] [Abstract][Full Text] [Related]
11. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease.
Niccolini F; Foltynie T; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Kapur S; Rabiner EA; Gunn RN; Piccini P; Politis M
Brain; 2015 Oct; 138(Pt 10):3003-15. PubMed ID: 26210536
[TBL] [Abstract][Full Text] [Related]
12. PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression.
Fazio P; Fitzer-Attas CJ; Mrzljak L; Bronzova J; Nag S; Warner JH; Landwehrmeyer B; Al-Tawil N; Halldin C; Forsberg A; Ware J; Dilda V; Wood A; Sampaio C; Varrone A;
Mov Disord; 2020 Apr; 35(4):606-615. PubMed ID: 31967355
[TBL] [Abstract][Full Text] [Related]
13. Lack of age-dependent decrease in dopamine D3 receptor availability: a [(11)C]-(+)-PHNO and [(11)C]-raclopride positron emission tomography study.
Nakajima S; Caravaggio F; Boileau I; Chung JK; Plitman E; Gerretsen P; Wilson AA; Houle S; Mamo DC; Graff-Guerrero A
J Cereb Blood Flow Metab; 2015 Nov; 35(11):1812-8. PubMed ID: 26058690
[TBL] [Abstract][Full Text] [Related]
14. Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia.
Kubota M; Takahata K; Matsuoka K; Sano Y; Yamamoto Y; Tagai K; Tarumi R; Suzuki H; Kurose S; Nakajima S; Shiwaku H; Seki C; Kawamura K; Zhang MR; Takahashi H; Takado Y; Higuchi M
Schizophr Bull; 2023 May; 49(3):688-696. PubMed ID: 36458958
[TBL] [Abstract][Full Text] [Related]
15. Reward motivation in humans and its relationship to dopamine D
Caravaggio F; Fervaha G; Browne CJ; Gerretsen P; Remington G; Graff-Guerrero A
J Psychopharmacol; 2018 Mar; 32(3):357-366. PubMed ID: 29442593
[TBL] [Abstract][Full Text] [Related]
16. Exploring personality traits related to dopamine D2/3 receptor availability in striatal subregions of humans.
Caravaggio F; Fervaha G; Chung JK; Gerretsen P; Nakajima S; Plitman E; Iwata Y; Wilson A; Graff-Guerrero A
Eur Neuropsychopharmacol; 2016 Apr; 26(4):644-52. PubMed ID: 26944295
[TBL] [Abstract][Full Text] [Related]
17. Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain.
Van Laere K; Ahmad RU; Hudyana H; Dubois K; Schmidt ME; Celen S; Bormans G; Koole M
J Nucl Med; 2013 Aug; 54(8):1285-93. PubMed ID: 23843566
[TBL] [Abstract][Full Text] [Related]
18. Validity and reliability of extrastriatal [
Svensson JE; Schain M; Plavén-Sigray P; Cervenka S; Tiger M; Nord M; Halldin C; Farde L; Lundberg J
Neuroimage; 2019 Nov; 202():116143. PubMed ID: 31473354
[TBL] [Abstract][Full Text] [Related]
19. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease.
Miller S; Hill Della Puppa G; Reidling J; Marcora E; Thompson LM; Treanor J
J Huntingtons Dis; 2014; 3(4):333-41. PubMed ID: 25575954
[TBL] [Abstract][Full Text] [Related]
20. The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects.
Tolboom N; Berendse HW; Leysen JE; Yaqub M; van Berckel BN; Schuit RC; Ponsen MM; Bakker E; Hoetjes NJ; Windhorst AD; Carlsson ML; Lammertsma AA; Carlsson A
Neuropsychopharmacology; 2015 Jan; 40(2):472-9. PubMed ID: 25248987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
